BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Biologics

Kelun-Biotech’s Sac-TMT–Keytruda Combination Outperforms Standard First-Line Therapy in Phase III Lung Cancer Trial

As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-L...

July 16, 2026 | News

GEM Commits Up to $15.5M to Back Senhwa Biosciences’ Oncology Pipeline

GEM Global Yield LLC SCS ("GEM") has executed a Share Purchase Agreement (the "SPA") with the existing shareholders of Taiwan-listed Senhwa Biosciences Inc...

July 16, 2026 | News

Delonix Bioworks Doses First Participant in China Phase 1 Trial of Next-Generation MenB Vaccine DX-104

Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, announced that the first participant has bee...

July 15, 2026 | News

Leads Biolabs' Opamtistomig Receives China's Priority Review for Advanced Neuroendocrine Cancer

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license application (BLA) for Op...

July 14, 2026 | News

Pfizer and Astellas Expand FDA Approval of PADCEV Plus Keytruda Across All Muscle-Invasive Bladder Cancer Patients

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced that the U.S. Food and Dru...

July 14, 2026 | News

Takeda Backs Indonesia's Plasma Ambitions with US$30 Million Investment to Build ASEAN's First Integrated Plasma Ecosystem

Ministry of Health of the Republic of Indonesia Grants Plasma Fractionation License, Enabling Takeda to Collect and Fractionate Plasma as Part of Multi...

July 14, 2026 | News

Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?

Scope 3 clauses, single-use plastic, water and energy intensity: the “green premium” has become the defining question for the CDMOs that built ...

July 14, 2026 | Analysis

HanchorBio Partners with InxMed to Explore New Combination Strategies for Lead Cancer Therapy

Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist I...

July 13, 2026 | News

WuXi Biologics' Hebei Facility Clears US FDA Pre-License Inspection for Commercial Manufacturing

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance ma...

July 13, 2026 | News

China Grants Priority Review to Leads Biolabs' Opamtistomig for Advanced Neuroendocrine Cancer

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced that the biologics license application (BLA) for Op...

July 13, 2026 | News

Abcam and EpiCypher Partner to Advance High-Confidence Epigenomics Research

Abcam, a Danaher company and a global provider of validated antibodies and assay solutions, and EpiCypher®, the leading provider of ChIC...

July 10, 2026 | News

QIAGEN Expands Philippines Presence with Experience Lab and Strategic Distribution Partnership

Partnership with Hamburg Trading Corp to advance applied testing and life science research Serving as a learning hub to empower the next generatio...

July 10, 2026 | News

APAC's Peptide-Capacity Gamble

For most of pharmaceutical history, the hard part was finding a molecule that worked. The GLP-1 class inverted that logic. The science arrived first &mdash...

July 09, 2026 | Analysis

Everest Medicines Closes Global Civorebrutinib Licensing Deal Worth Up to $1.14 Billion

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

July 09, 2026 | News

Stay Connected